

Q4 20-21 Performance in Delivering

Study Protocol Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
50475	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Number Agreed	3	3	Date Agreed	29/07/2020	0	24/07/2020	0	Recruitment Finished	early finish - closed by sponsor
50476	17/EE/0402	224923	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991 I	Number Agreed	0	0	Date Agreed	30/09/2020	0	24/07/2020	0	Recruitment Finished	feeder study closed with ) patients, no patients to roll over therefore closed
50477	18/LO/1387	246858	An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials.	Number Agreed	0	0	Date Agreed	25/12/2022	0	06/10/2020	0	Withdrawn By Sponsor	Study was withdrawn by Sponsor at site as the original study has had early termination and we had no patients who were due to roll onto this open label trial
50478	19/YH/0400	271539	A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of	Number Agreed	3	3	Date Agreed	31/03/2021	0	27/11/2020	0	Withdrawn By Host	No eligible patients - Due to COVID we have seen a decrease in admission of these patients.
50480	19/LO/0697	250792	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE)	Number Agreed	2	2	Date Agreed	23/06/2021	0	04/02/2021	0	Withdrawn By Host	No eligible patients - Due to COVID we have seen a decrease in admission of these patients.
50481	19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	2	Date Agreed	30/06/2021	0	17/02/2021	0	Withdrawn By Host	No eligible patients - Due to COVID we have seen a decrease in admission of these patients.